27 January 2023
This recent study describes the recurrence risk, progression patterns, response to subsequent treatment, and survival of patients with advanced melanoma who ceased targeted therapy prior to disease progression. It concludes that the risk of progression after cessation of targeted therapy is strongly associated with treatment duration. Response to retreatment with targeted therapy is high.
27 January 2023
The objective of this recent study was to build a worldwide usable matrix of UV radiation exposure in occupations and to show use cases for the data. It hopes to enable sound studies on the nature of UV-induced skin cancer, dose–response relationships, intermittency of skin exposure, and derivation of limit values and to make sociological studies on prevention possible. Practitioners may use the findings for their daily work with employees.
15 January 2023
According to this study, melanoma thickness at diagnosis is significantly associated with quality of patients' diets before diagnosis.
14 January 2023
Adjuvant pembrolizumab significantly improved recurrence-free survival versus placebo in stage IIB or IIC melanoma in the first interim analysis of the KEYNOTE-716 trial. Here, authors report results from the secondary endpoint of distant metastasis-free survival (prespecified third interim analysis), and recurrence-free survival with longer follow-up. They conclude that the overall benefit–risk of pembrolizumab continues to be positive in the adjuvant setting.
14 January 2023
According to this recent study, a blood test based on circulating microRNAs can non-invasively detect melanoma, offering a novel diagnostic tool for improving standard care.
14 January 2023
According to this recent study, neoadjuvant immune checkpoint inhibitors (ICI) treatment has potential to avert mutilating treatments in non-melanoma skin cancers. Progress can be accelerated by learning from melanoma.
14 January 2023
Findings of this recent study provide new insights into the motivations for participating in genomics research and highlight the need to better target population subgroups including younger men, which will aid in tailoring recruitment for future melanoma genomic studies.
12 January 2023
Authors of this recent study examined the efficacy of checkpoint inhibitors in acral melanoma. It concludes that while the objective response rate to anti-PD-1/ipilimumab was significantly higher than anti-PD-1 and progression-free survival numerically higher, this benefit did not translate to improved overall survival. Future trials should specifically include patients with acral melanoma, to help determine the optimal management of this important melanoma subtype.
12 January 2023
This study aimed to determine the efficacy and safety of anti-PD1 (PD1) versus IPI (anti-CTLA-4) +PD1 after BRAF/MEK inhibitors (BRAF/MEKi). It concludes that IPI+PD1 and PD1 have similar outcomes, however, IPI+PD1 is more toxic.
12 January 2023
This recent study concludes that in patients with melanoma brain metastasis (MBM), the addition of radiotherapy resulted in a favorable overall survival (OS) on systemic therapy. In BRAF-mutated MBM patients, immune checkpoint blockade as first-line therapy and BRAF+MEK as second-line therapy were associated with a significantly prolonged OS.
